Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?

Journal of Hepatology

Volumn 54, Issue 4, 2011, Pages 835-836

  Lagging, Martin ^a   Alsiö, Åsa ^a   Hellstrand, Kristoffer ^a   Norkrans, Gunnar ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIMIT OF DETECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLICATION; RNA ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 79952704334     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.09.038     Document Type: Letter

References (7)

1. Sarrazin C, Shiffman ML, Hadziyannis SJ, Lin A, Colucci G, Ishida H, et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 2010;52:832-838.
2. Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
3. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134. (Pubitemid 47057730)
4. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837-1845. (Pubitemid 351945551)
5. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology 2008;48:695.
6. Sarrazin C, Dragan A, Gartner BC, Forman MS, Traver S, Zeuzem S, et al. Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol 2008;43:162-168.
7. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008;46:3880-3891.